Evidence map›Paper›PMID 33824674›Full record

ReviewJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences2020

N-acetylcysteine and coronavirus disease 2019: May it work as a beneficial preventive and adjuvant therapy? A comprehensive review study.

Najmolsadat Atefi, Elham Behrangi, Samaneh Mozafarpoor, Farnoosh Seirafianpour, Shadi Peighambari, Azadeh Goodarzi

Open access · goldAbstract readReview
In one paragraph

Review in Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 5 pooled it
0.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 5 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Review
  9. Beneficial esthetic lightening effects ofJournal of family medicine and primary care · 2022
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. N-Acetylcysteine and Other Sulfur-Donors as a Preventative and Adjunct Therapy for COVID-19.Advances in pharmacological and pharmaceutical sciences · 2022
    Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. The effect of opium on severity of COVID-19 infection:An original study from Iran.Medical journal of the Islamic Republic of Iran · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Najmolsadat AtefiDepartment of Dermatology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Elham BehrangiDepartment of Dermatology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Samaneh MozafarpoorDepartment of Dermatology, Skin Disease and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Farnoosh SeirafianpourDepartment of General Medicine, Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran.
Shadi PeighambariDepartment of Internal Medicine, San Joaquin General Hospital, CA, USA.
Azadeh GoodarziDepartment of Dermatology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Iran University of Medical Sciences · IRIsfahan University of Medical Sciences · IRRasool Akram Hospital · IRSan Joaquin General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronaviruses are major pathogens of respiratory system causing different disorders, including the common cold, Middle East respiratory syndrome, and severe acute respiratory syndrome. Today's global pandemic coronavirus disease 2019 (COVID-19) has high mortality rate, with an approximate of 20% in some studies, and is 30-60 times more fatal than the common annual influenza, However, there is still no gold standard treatment for it. N-acetylcysteine (NAC) is a well-known multi-potential drug with hypothetically probable acceptable effect on COVID-related consequences, which we completely focused in this comprehensive review. MATERIALS AND

methodsPubMed, Scopus, Science Direct, and Google Scholar have been searched. Study eligibility criteria: efficacy of NAC in various subclasses of pathogenic events which may occur during COVID-19 infection. Efficacy of NAC for managing inflammatory or any symptoms similar to symptoms of COVID-19 was reviewed and symptom improvements were assessed.

resultsRandomized clinical trials introduced NAC as an antioxidant glutathione analog and detoxifying agent promoted for different medical conditions and pulmonary disorders to alleviate influenza and reduce mortality by 50% in influenza-infected animals. The beneficial effects of NAC on viral disorders, including Epstein-Barr virus, HIV and hepatitis, and well-known vital organ damages were also exist and reported.

conclusionWe classified the probable effects of NAC as oxidative-regulatory and apoptotic-regulatory roles, antiviral activities, anti-inflammatory roles, preventive and therapeutic roles in lung disorders and better oxygenation functions, supportive roles in intensive care unit admitted patients and in sepsis, positive role in other comorbidities and nonpulmonary end-organ damages or failures and even in primary COVID-associated cutaneous manifestations. Based on different beneficial effects of NAC, it could be administered as a potential adjuvant therapy for COVID-19 considering patient status, contraindications, and possible drug-related adverse events.

Indexed as

Acute respiratory distress syndromeadjuvant therapyanti-inflammatoryanti-oxidantanti-viralcomprehensive reviewcoronavirusCOVID-19N-acetylcysteineorgan failurepreventionpulmonaryrespiratorytreatment

Identifiers

PMID33824674
PMCPMC8019127
OpenAlexW3109802806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.